landiolol has been researched along with dobutamine in 4 studies
| Studies (landiolol) | Trials (landiolol) | Recent Studies (post-2010) (landiolol) | Studies (dobutamine) | Trials (dobutamine) | Recent Studies (post-2010) (dobutamine) |
|---|---|---|---|---|---|
| 311 | 85 | 176 | 6,357 | 818 | 1,011 |
| Protein | Taxonomy | landiolol (IC50) | dobutamine (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 1 | Homo sapiens (human) | 4.17 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 5.551 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 5.519 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 3.975 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 1.517 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.383 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 1.944 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 0.599 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 2.966 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.383 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.114 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 1.895 | |
| D(3) dopamine receptor | Homo sapiens (human) | 4.985 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.155 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 2.518 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawashima, S; Kurita, T; Morita, K; Nakajima, Y | 1 |
| Hodisch, J; Kadlecová, P; Krumpl, G; Trebs, M; Ulč, I | 1 |
| Hodisch, J; Husch, B; Kadlecová, P; Krumpl, G; Trebs, M; Ulč, I | 1 |
| Ishii, T; Izawa, K; Kinoshita, M; Masuda, M; Onoda, T; Sato, N; Tanaka, H; Urano, A | 1 |
2 trial(s) available for landiolol and dobutamine
| Article | Year |
|---|---|
Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Cardiotonic Agents; Cross-Over Studies; Dobutamine; Double-Blind Method; Female; Healthy Volunteers; Heart Rate; Humans; Infusions, Intravenous; Male; Morpholines; Prospective Studies; Urea; Young Adult | 2020 |
Blood Pressure Recovery After Dobutamine Antagonism: Partial With Landiolol, None With Esmolol.
Topics: Blood Pressure; Cross-Over Studies; Dobutamine; Humans; Morpholines; Propanolamines; Prospective Studies; Urea | 2022 |
2 other study(ies) available for landiolol and dobutamine
| Article | Year |
|---|---|
Dobutamine, a β1 Adrenoceptor Agonist, Increases Cerebral Oxygenation During Acute Anemia and Apneic Hypoxia.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-Antagonists; Animals; Apnea; Cerebrum; Disease Models, Animal; Dobutamine; Hypoxia; Morpholines; Oxygen Consumption; Spectroscopy, Near-Infrared; Swine; Urea | 2017 |
[Chemical Stability after Mixing Continuous Infusion Drugs Used to Treat Cardiogenic Shock].
Topics: Dobutamine; Humans; Milrinone; Norepinephrine; Pharmaceutical Preparations; Shock, Cardiogenic | 2022 |